Vinblastine

Generic Name: Vinblastine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₈N_₄O_₉

CAS Number: 865-21-4

Unique Ingredient Identifier: 5V9KLZ54CY

Background: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication: For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Associated Conditions: Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer

Associated Therapies: -

Clinical Trials

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Phase 1

Completed

Conditions: Stage IV Skin Melanoma
Recurrent Melanoma

Interventions: Drug: Cisplatin
Drug: Gamma-Secretase Inhibitor RO4929097
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Vinblastine Sulfate

First Posted Date: 2010-09-08

Last Posted Date: 2019-11-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT01196416

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Phase 3

Completed

Conditions: Elderly Patients (>65 Years)
Diffuse Large B Cell Lymphoma (DLBCL)

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone
Drug: Vinblastine
Drug: Rituximab
Drug: G-CSF

First Posted Date: 2010-06-22

Last Posted Date: 2010-06-22

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 226

Registration Number: NCT01148446

Locations: 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
S.C. di Ematologia, Spedali Civili, Brescia, Italy

and more 8 locations

Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Vinblastine
Radiation: Radiation therapy

First Posted Date: 2010-06-02

Last Posted Date: 2015-03-27

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 610

Registration Number: NCT01134861

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Phase 1

Completed

Conditions: Disease, Hodgkin

Interventions: Drug: vinblastine
Drug: doxorubicin
Drug: brentuximab vedotin
Drug: dacarbazine
Drug: bleomycin

First Posted Date: 2010-02-02

Last Posted Date: 2014-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 51

Registration Number: NCT01060904

Locations: 🇺🇸
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Doxorubicine
Drug: DTIC
Drug: Lenalidomide
Drug: Vinblastine

First Posted Date: 2010-01-26

Last Posted Date: 2018-03-22

Lead Sponsor: University of Cologne

Target Recruit Count: 30

Registration Number: NCT01056679

Locations: 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, NRW, Germany

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Phase 2

Completed

Conditions: Bladder Cancer
Muscle-invasive Bladder Cancer

Interventions: Drug: Methotrexate
Drug: Doxorubicin
Drug: vinblastine
Drug: cisplatin
Drug: Pegfilgrastim

First Posted Date: 2008-12-16

Last Posted Date: 2016-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00808639

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Phase 2

Completed

Conditions: Classic Hodgkin Lymphoma
Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Lugano Classification Stage III Hodgkin Lymphoma AJCC v8

Interventions: Drug: Bleomycin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Biological: Rituximab
Drug: Vinblastine

First Posted Date: 2008-04-09

Last Posted Date: 2020-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00654732

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2008-03-14

Last Posted Date: 2015-10-08

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 41

Registration Number: NCT00635726

Locations: 🇬🇷
IASO General Hospital of Athens, 1st Dept. of Medical Oncology, Athens, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupolis, Greece
🇬🇷
Metaxa's Anticancer Hospital of Piraeus, 1st Dept. of Medical Oncology, Piraeus, Greece

and more 4 locations

Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)

Phase 2

Conditions: Glioma

Interventions: Drug: Vinblastine Sulphate

First Posted Date: 2007-12-18

Last Posted Date: 2017-09-20

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 50

Registration Number: NCT00575796

Locations: 🇨🇦
Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
🇨🇦
Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada

and more 14 locations

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Phase 2

Completed

Conditions: Renal Cell Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: Interferon alfa-2a
Drug: Vinblastine

First Posted Date: 2007-08-24

Last Posted Date: 2014-10-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 25

Registration Number: NCT00520403

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy